Biogen Idec Appoints Head of Gene Therapy

From DCAT Value Chain Insights (VCI)

By People On The Move posted 09-23-2014 12:05


Biogen Idec has appointed Oliver Danos, PhD as senior vice president, gene therapy. He will report directly to Douglas Williams, Ph.D., executive vice president, research and development, and is a member of Biogen Idec’s senior research and development leadership team.

Danos will lead the company’s gene-therapy research group, a team dedicated to identifying and developing new technologies for gene transfer and genome engineering. As part of his role, he will also identify potential collaborations that complement the company’s internal capabilities and support the development of treatments across Biogen Idec’s therapeutic focus areas.

Dr. Danos joins Biogen Idec from Kadmon Pharmaceuticals, where he served as senior vice president, Molecular Medicine, Synthetic Biology and Gene Regulation since 2011. In this role, he was instrumental in assembling a gene-therapy program and a technology platform for the development of controllable gene-expression systems. Prior to Kadmon, Dr. Danos acted as the director of the Gene Therapy Consortium of the University College of London and led a gene-therapy research team at the Necker Hospital–Enfants Malades in Paris. He also served as chief scientific officer at Genethon and senior director of research at Somatix Therapy Corporation. He has held several senior roles at the French National Center for Scientific Research and at the Institut Pasteur in Paris. He is the former president and a founding member of the European Society of Gene and Cell Therapy.

Source: Biogen Idec



Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription